Helus Pharma Inc. Common Stock (HELP) Stock Price

HELPStock
$10.55+76.06%52W
Market Cap$770.88M
P/E—
PEG Ratio—
Div yield—
Beta0.52

HELP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)90.23%
Price vs S&P 500 (4W)-13.20%
VGM Score83.80

HELP Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.98-$0.89+8.37%(+$0.08)
Q1 2026-$0.81-$0.85-5.77%(-$0.05)
Q4 2025-$0.69-$0.96-39.79%(-$0.28)
Q3 2025-$0.94-$1.17-24.53%(-$0.23)
Q2 2025-$0.78-$0.69+11.98%(+$0.09)

HELP Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.25
4.25
4.25

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
HELPHelus Pharma Inc. Common Stock
——A————$10.55
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Helus Pharma Inc. Common Stock

Helus Pharma is a clinical-stage biopharmaceutical company developing serotonergic agonists to treat mental health disorders, including depression and anxiety. The company's lead candidate, HLP003, is in Phase 3 development for adjunctive treatment of major depressive disorder. With operations across North America and Europe, Helus Pharma addresses an underserved market for innovative neuropsychiatric therapies.